J3262 Tocilizumab injection
Also known as: tocilizumab, Actemra, interleukin-6 receptor inhibitor
Tocilizumab injection is a humanized monoclonal antibody targeting interleukin-6 receptor used for rheumatoid arthritis, giant cell arteritis, and other inflammatory conditions.
In Plain Language
arthritis treatment injection; inflammation medication
Clinical Context
Indicated for moderate to severe rheumatoid arthritis, giant cell arteritis, and systemic sclerosis-associated interstitial lung disease. Blocks interleukin-6 signaling to reduce inflammation. Administered intravenously or subcutaneously.
RVU Information
CPT J3262 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.
Billing & Documentation
J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.
Specialties
Frequently Asked Questions
What is CPT code J3262?
CPT J3262 (Tocilizumab injection) is a J Codes (Drugs) code. Tocilizumab injection is a humanized monoclonal antibody targeting interleukin-6 receptor used for rheumatoid arthritis, giant cell arteritis, and other inflammatory conditions.
How is J3262 administered?
CPT J3262 is administered by a healthcare provider, typically via injection or infusion. Indicated for moderate to severe rheumatoid arthritis, giant cell arteritis, and systemic sclerosis-associated interstitial lung disease. Blocks interleukin-6 signaling to reduce inflammation. Administered intravenously or subcutaneously. It is used by Rheumatology, Internal Medicine, Infectious Disease.
When is CPT J3262 used?
Indicated for moderate to severe rheumatoid arthritis, giant cell arteritis, and systemic sclerosis-associated interstitial lung disease. Blocks interleukin-6 signaling to reduce inflammation. Administered intravenously or subcutaneously.
Track This Code in RVU Edge
Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.
CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.